Kaletra Capsules (Lopinavir, Ritonavir Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news
Improvement of Lipoatrophy by Switching From EFV to LPV/r Improvement of Lipoatrophy by Switching From EFV to LPV/r
Switching HIV patients with lipoatrophy from efavirenz to lopinavir/ritonavir may affect positive changes in limb fat.HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents
Could oral contraceptives containing ethinyl estradiol/desogestrel compromise the effectiveness of lopinavir/ritonavir-based therapy?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 24, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir
El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos medicamentos cuando se usan conjuntamente (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2016 Category: Drugs & Pharmacology Source Type: news
Efavirenz linked with higher bone mass in children with HIV
BOSTON – Switching HIV-infected South African children from ritonavir-boosted lopinavir (LPV/r) to efavirenz (EFV)-based antiretroviral therapy improved bone mineral content in the children, compared... (Source: Pediatric News)
Source: Pediatric News - February 25, 2016 Category: Journals (General) Source Type: news
South Africa: Aids Day Highlights Need to Fix Patents Law
[News24Wire] The country's patent law is yet again under the microscope in light of World Aids Day and following the recent shortage of HIV medicine Lopinavir/Ritonavir (LPV/r), which is a life-line for nearly 10% of the country's approximately 3 million people on HIV treatment. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 1, 2015 Category: African Health Source Type: news
CHMP Backs Generic Lopinavir/Ritonavir Mylan for HIVCHMP Backs Generic Lopinavir/Ritonavir Mylan for HIV
Studies demonstrate the satisfactory quality of Lopinavir/Ritonavir Mylan and its bioequivalence to the reference product Kaletra, the committee said. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2015 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news
Switch to Efavirenz-based ART Effective Option in KidsSwitch to Efavirenz-based ART Effective Option in Kids
A new study has found that switching to efavirenz-based ART vs continuing on ritonavir-boosted lopinavir-based ART was not tied to higher rates of viral rebound and failure in children. Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 5, 2015 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
South Africa Should Override Patent on Key HIV Medicine After Widespread Stock Out Problem
Press releaseSouth Africa Should Override Patent on Key HIV Medicine After Widespread Stock Out Problem
October 28, 2015
JOHANNESBURG—After six months of persistent supply problems with the key HIV medicine lopinavir/ritonavir (LPV/r), the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) urged the South African government to put the public’s health first and override pharmaceutical company AbbVie’s patent with a "compulsory licence," in order to allow generic versions of LPV/r to be used in the country. (Source: MSF News)
Source: MSF News - October 28, 2015 Category: Global & Universal Authors: Elias Primoff Source Type: news
South Africa: Red Flag Over HIV Medicine Stock Out
[News24Wire] Doctors Without Borders wants the South African government to issue a landmark compulsory license to allow generic manufacturers to come to the aid of thousands of HIV patients in need of Lopinavir/Ritonavir (LPV/r). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - October 28, 2015 Category: Infectious Diseases Source Type: news
There May Have Been a Major Breakthrough in MERS Treatment
Two existing and widely available drugs may prove to be effective treatments for Middle East Respiratory Syndrome (MERS), new research published by the University of Hong Kong suggests.
According to the South China Morning Post, the medicines—lopinavir with ritonavir and a type of interferon—were tested on marmosets, small monkeys that a 2014 U.S. study concluded would be the best subject for MERS trials because of the way their reactions to the virus mimics human illness. The drugs, currently used to treat HIV and sclerosis, were found to be effective in curing MERS-infected marmosets.
The research is the firs...
Source: TIME.com: Top Science and Health Stories - July 28, 2015 Category: Consumer Health News Authors: alissagreenberg Tags: Uncategorized Hong Kong medicine MERS monkeys Science South Korea Source Type: news
lopinavir and ritonavir, Kaletra
Title: lopinavir and ritonavir, KaletraCategory: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 7/9/2015 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - July 9, 2015 Category: Infectious Diseases Source Type: news
FDA Updates Kaletra Labeling
"The Kaletra (lopinavir/ritonavir) product labeling was updated to include drug-drug interaction information with etravirine, rilpivirine and simeprevir and to update the Use in Specific Populations, Pediatric Use subsection with information from a clinical trial that investigated the use of a once daily dosing regimen."
The updated labeling will be available soon at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on Kaletra (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Departm...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 2, 2015 Category: Infectious Diseases Source Type: news
FDA Approves First Pediatric Lopinavir/Ritonavir Oral Pellets for the Treatment of AIDS in Infants and Young Children
Mumbai, India - June 3, 2015 --Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it has received US FDA approval for an innovative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 3, 2015 Category: Pharmaceuticals Source Type: news
Cipla gets USFDA nod for Lopinavir, Ritonavir oral pellets
Cipla has received approval from US health regulator USFDA for Lopinavir and Ritonavir oral pellets used for treating AIDS in infants and young children. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 3, 2015 Category: Pharmaceuticals Source Type: news
